Chinese Herbal Medicine in Acute INtracerebral Haemorrhage (CHAIN) Trial

Intracerebral Hemorrhage Clinical Trial

Official title:

An Investigator-initiated and Conducted Multicentre, Prospective, Randomised, Double-blinded Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Chinese Herbal Medicine in Patients With Acute Intracerebral Haemorrhage

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05066620
• Other study ID #: 2020B1111100009
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: October 2021
• Est. completion date: January 2025

Study information

• Verified date: September 2021
• Source: Guangzhou University of Traditional Chinese Medicine
• Contact: Jianwen Guo, MD
• Phone: +86-13724899379
• Email: jianwen_guo[@]qq.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

TCM is an essential context of the ICH management in Chinese culture. Given the potential benefits of Chinese herbal medicine FYTF-919 in reducing haematoma and bleeding after acute ICH from fundamental research and small clinical studies, more reliable evidence is required to guide ICH treatment using TCM. This study aims to determine the effectiveness and safety of TCM in a larger sample of patients with moderate-severe ICH and provide evidence for TCM clinical guidelines on ICH management. The presumed mechanism of action is in promoting the reabsorption of the haematoma and perihematomal oedema in ICH.

Description:

A multicentre, prospective, randomised, double-blind, placebo-controlled trial to be conducted through hospital network of investigators in China. A total of 1504 patients with ICH will be recruited from approximately 20-30 hospitals. Randomised is via a central internet-based system according to block random grouping method stratified by site, neurological severity NIHSS <15 vs ≥15), and haematoma location (basal ganglia + lobe vs thalamus + cerebellum + brain stem + ventricle) to ensure balance in key prognostic factors. Endpoint assessment will be blinded to treatment allocation. The primary aim of this study is to determine the effectiveness and safety of a Chinese herbal medicine FYTF-919 as compared to placebo on functional recovery according to Utility-weighted modified Rankin scale (UW-mRS) at 90 days after acute ICH. Secondary aims include examining whether the Chinese herbal medicine FYTF-919 leads to positive treatment effect on: 1) Utility-weighted mRS scores at 180 days; 2)Ordinal analysis of 7 levels of mRS at 28 days, 90 days and 180 days; 3) Poor prognosis, defined as mRS 4-6 points at 28 days, 90 days and 180 days; 4) NIHSS score at 7 days and 28 days; 5) Mortality rate at 28 days, 90 days and 180 days; 6) Discharge rate at 28 days; 7) EQ-5D-5L at 28days, 90 days and 180 days; 8) BI at 28 days, 90 days and 180 days; 9) The cerebral edema volume at baseline, 24 hours, 7 days, 14 days or at discharge; 10) The hematoma volume at baseline, 24 hours, 7 days, 14 days or discharge; 11) The incidence of stroke-associated pneumonia (SAP) patients; 12) Clinical pulmonary infection score (CIPS) at the onset of SAP, 3 days, and 7 days, after the occurrence of SAP; 13) Chest imaging (DR/CT), body temperature, white blood cell count, C-reactive protein (CRP), procalcitonin (PCT) blood gas analysis, and sputum culture/airway aspirate culture at the onset of SAP, 3 days, and 7 days after the occurrence of SAP; 14) Antibiotic usage among patients with SAP.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 1504
• Est. completion date: January 2025
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age =18 years;

2. Diagnosis of spontaneous ICH, confirmed by brain imaging;

3. Presentation within 48 hours of symptom onset (or last seen well);

4. Meet any of the following criteria: a) NIHSS =8, or b) GCS 7-14;

5. Provide written informed consent by patient (or approved surrogate);

Exclusion Criteria:

1. ICH secondary to a structural abnormality in the brain (e.g. cerebrovascular malformation, arterial aneurysm, tumour, Moyamoya disease, trauma, or previous ischaemic stroke), or secondary to presumed cerebrovascular amyloidosis, or secondary to reperfusion treatment for ischaemic stroke, or secondary to anticoagulant treatment, or secondary to antiplatelet treatment.

2. Unlikely to potentially benefit from therapy (e.g. advanced dementia) or judged by responsible treating clinician to have a high likelihood of early death irrespective of treatment;

3. Other medical illness that will interfere with outcome assessments and follow-up (e.g. known significant pre-stroke disability [modified Rankin scale {mRS} scores 4-5], advanced cancer and renal failure);

4. Known definite contraindication to the Chinese herbal medicine;

5. Women who are known to be pregnant or lactating;

6. Currently participating in another trial which would interfere with outcome assessments.

Related Conditions & MeSH terms

• Cerebral Hemorrhage
• Hemorrhage
• Intracerebral Hemorrhage

Intervention

Drug:
• Chinese herbal medicine FYTF-919
Oral liquid 33ml TID (for patients who are unconscious or dysphagia, a dose of 25ml * Q6H will be given through nasal feeding)

Locations

Country	Name	City	State
China	Guangdong Provincial Hospital of Chinese Medicine	Guangzhou	Guangdong

Sponsors (2)

Lead Sponsor	Collaborator
Guangzhou University of Traditional Chinese Medicine	The George Institute

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Utility-weighted modified Rankin scale scores	Utility-weighted modified Rankin scale scores. The value range from 0 to 10: higher scores mean a better outcome.	90 days after the treatment started
Secondary	Utility-weighted mRS scores	Utility-weighted modified Rankin scale scores. The value range from 0 to 10: higher scores mean a better outcome.	180 days after the treatment started
Secondary	7 levels of mRS	Ordinal analysis of 7 levels of mRS. The value range 0-6: higher scores mean a worse outcome.	28 days, 90 days and 180 days after the treatment started
Secondary	Poor prognosis rate	Binary variable: 1 means mRS 4-6 points; 0 means mRS is 0-3 points.	28 days, 90 days and 180 days after the treatment started
Secondary	NIHSS score	National Institute of Health Stroke Scale Score. The value range 0-42: higher scores mean a worse outcome.	7 days and 28 days after the treatment started
Secondary	Mortality rate	Mortality rate	28 days, 90 days and 180 days
Secondary	Discharge rate	Discharge rate	28 days after the treatment started
Secondary	European Quality of Life 5-dimensional questionnaire (EQ-5D-5L)	The EQ-5D comprises five dimensions of health: mobility, ability to self-care, ability to undertake usual activities, pain and discomfort, and anxiety and depression. . EQ-5D-5L, includes five levels of severity for each dimension (no problems, slight problems, moderate problems, severe problems, and extreme problems). The value range 0-100: higher scores mean a worse outcome.	28 days, 90 days and 180 days after the treatment started
Secondary	BI	Barthel index. The value range 0-100: higher scores mean a better outcome.	28 days, 90 days and 180 days after the treatment started
Secondary	The cerebral edema volume	The cerebral edema volume	Baseline, 24 hours, 7 days, 14 days or at discharge
Secondary	The hematoma volume	The hematoma volume	Baseline, 24 hours, 7 days, 14 days or discharge
Secondary	SAP	The incidence of stroke-associated pneumonia patients	Baseline, 24 hours, 7 days, 14 days or discharge
Secondary	CPIS	Clinical pulmonary infection score. The value range 0-12: higher scores mean a worse outcome.	The onset of SAP, 3 days and 7 days after the occurrence of SAP
Secondary	Pulmonary infection	Diagnosed by using the Chest imaging (DR/CT), body temperature, white blood cell count, C-reactive protein (CRP), procalcitonin (PCT) blood gas analysis, and sputum culture/airway aspirate culture	The onset of SAP, 3 days and 7 days after the occurrence of SAP
Secondary	Antibiotic usage	Antibiotic usage among patients with SAP	The onset of SAP, 3 days and 7 days after the occurrence of SAP